Claims for Patent: 10,933,147

Summary for Patent: 10,933,147

Title:	Imaging of metastatic or recurrent cancer
Abstract:	The present disclosure relates to methods of administering [.sup.18F]-FACBC. The present disclosure also relates to use of [.sup.18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer.
Inventor(s):	Miller; Matthew (Oxford, GB), Gauden; David (Oxford, GB), Schuster; David (Atlanta, GA), Fanti; Stefano (Bologna, IT), Nanni; Cristina (Bologna, IT), Zanoni; Lucia (Bologna, IT), Willoch; Frode (Oslo, NO), Bogsrud; Trond (Oslo, NO), Bach-Gansmo; Tore (Oslo, NO), Musto; Alessandra (Bologna, IT)
Assignee:	Blue Earth Diagnostics Limited (Oxford, GB)
Application Number:	16/907,779
Patent Claims:	1. A method of administering anti-1-amino-3-.sup.18F-fluorocyclobutane-1-carboxylic acid ([.sup.18F]-FACBC) for a positron emission tomography (PET) scan, comprising: a) administering the [.sup.18F]-FACBC as an intravenous bolus injection into a human subject having a suspected prostate cancer recurrence; and b) acquiring a PET scan image of at least a pelvic region of the human subject while the human subject positions arms above the head, wherein the PET scan starts 3 to 5 minutes after the end of the injection of the [.sup.18F]-FACBC, and wherein the human subject has followed patient preparation parameters that include: i. for at least 4 hours prior to administering of the [.sup.18F]-FACBC, to consume no food or drink including water, except sips of water for taking medications, and ii. to avoid significant exercise from the day before the PET scan through to the time of the PET scan. 2. The method of claim 1, wherein between 250 MBq and 500 MBq of the [.sup.18F]-FACBC is administered. 3. The method of claim 1, wherein between 290 MBq and 450 MBq of the [.sup.18F]-FACBC is administered. 4. The method of claim 1, wherein 370.+-.20% MBq of the [.sup.18F]-FACBC is administered. 5. The method of claim 1, wherein 370 MBq of the [.sup.18F]-FACBC is administered. 6. The method of claim 5, further comprising analysing the acquired PET scan image for a lesion less than 1 cm in a location suspicious for the prostate cancer recurrence and having an [.sup.18F]-FACBC uptake greater than blood pool. 7. The method of claim 6, further comprising identifying such a lesion as being suspicious for the prostate cancer recurrence. 8. The method of claim 1, further comprising diluting the [.sup.18F]-FACBC prior to injection. 9. The method of claim 8, wherein diluting the [.sup.18F]-FACBC includes diluting the [.sup.18F]-FACBC up to 10 mL. 10. The method of claim 1, wherein the human subject is in a supine position with arms above the head when acquiring the PET scan image. 11. The method of claim 1, wherein the acquired PET scan image includes from at least a proximal thigh to a base of a skull of the human subject. 12. The method of claim 1, wherein the [.sup.18F]-FACBC is administered into an arm of the human subject when the arm of the human subject is adjacent to the human subject's torso.